Maresin 1 (MaR1, 7R,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) is the founding member of the maresin family of Specialized pro-resolving mediators (SPMs), biosynthesized from DHA via 12-LOX in activated macrophages. MaR1 potently promotes resolution of inflammation, enhances efferocytosis, accelerates tissue regeneration, and reduces both inflammatory and neuropathic pain through its primary receptor LGR6 and possibly nuclear receptor RORΞ±.
Think of MaR1 as the city's cleanup and reconstruction coordinator arriving after a riot. While IL-6 and other cytokines were the emergency broadcast system alerting everyone to the threat, and neutrophils were the riot police containing the damage, MaR1 shows up when it's time to restore order. It doesn't just tell the cleanup crews (M2 macrophages) to sweep up debrisβit hands them specialized vacuum cleaners that can identify and remove damaged cells without triggering another alarm. At the same time, MaR1 puts up "road closed" signs to prevent more riot police from flooding in, calls in construction teams (fibroblasts) to repair buildings, and even rewires the pain sensors so the neighborhood doesn't remain hypervigilant. Unlike a simple cease-fire (which would be basic anti-inflammatory action), MaR1 actively rebuilds trust and infrastructure, transforming the inflammatory battlefield back into functional tissue. The whole operation depends on having enough raw materials (DHA) in the city's supply chainβno DHA substrate means no MaR1 coordinator.
MaR1 biosynthesis follows a specific enzymatic cascade in activated M2 macrophages:
Biosynthetic Pathway:
DHA (22:6n-3) β 12-LOX (12-lipoxygenase) β 13S,14S-epoxy-maresin intermediate β hydrolysis β MaR1 (7R,14S-dihydroxy-DHA)
The biosynthetic process requires:
- S-form lipoxygenase (12-LOX) activity, particularly enriched in M2-polarized macrophages
- Adequate cellular DHA substrate from membrane phospholipids (released by PLA2G7)
- Local tissue pH >7.0 (acidic environments impair SPM synthesis)
- Intracellular calcium signaling to activate lipoxygenase enzymes
Receptor Signaling:
graph TD
A[MaR1] --> B[LGR6 Receptor]
A --> C["RORΞ± Nuclear Receptor"]
B --> D["GΞ±i/o Protein Coupling"]
D --> E["β cAMP / β PKA"]
D --> F[PI3K/Akt Activation]
F --> G[Enhanced Phagocytosis]
F --> H["β Efferocytosis Machinery"]
H --> I["β MerTK, β CD36, β Integrin Ξ±vΞ²3"]
C --> J[Gene Transcription Changes]
J --> K["β Resolution Program Genes"]
J --> L["β NF-ΞΊB Target Genes"]
B --> M[TRPV1 Channel Modulation]
M --> N["β Pain Signaling"]
Cellular Actions (MaR1 acts on multiple cell types):
-
Macrophages: MaR1 β LGR6 β β efferocytosis capacity (uptake of apoptotic cells) β β expression of MerTK receptor, CD36 scavenger receptor, integrin Ξ±vΞ²3 β non-phlogistic clearance (engulfment without inflammatory mediator release) β β TGF-beta secretion β tissue repair signaling
-
Neutrophils: MaR1 β β transendothelial migration β β L-selectin (CD62L) expression β β recruitment to inflamed tissue β β NETosis β accelerated resolution interval (Ri)
-
Platelets: MaR1 β β thromboxane A2 (TXA2) synthesis β β platelet aggregation β prevention of microthrombosis in inflamed tissue
-
Neuronal tissue: MaR1 β modulation of TRPV1 channels β β Substance P release from nociceptors β β central sensitization β analgesia without opioid receptor involvement β promotes nerve regeneration via neurotrophin upregulation
-
Bacterial clearance: MaR1 β β macrophage phagocytosis of bacteria (E. coli, S. aureus) β β antimicrobial peptide expression β bacterial clearance without excessive collateral tissue damage
Metabolic Inactivation:
MaR1 is rapidly metabolized by:
- 15-hydroxyprostaglandin dehydrogenase (15-PGDH) β 7R-keto-MaR1 (inactive)
- Ξ²-oxidation pathways β chain-shortened metabolites
- Half-life in vivo: approximately 4-6 hours (necessitating continuous SPM generation for sustained resolution)
Quantitative Thresholds:
- Effective concentrations in tissue: 1-100 nM range
- Peak MaR1 production: 12-24 hours after inflammatory stimulus (coinciding with resolution phase)
- DHA substrate requirement: phospholipid membrane DHA >4% of total fatty acids for optimal SPM synthesis
MaR1 represents the molecular embodiment of Lipid mediator class switchingβthe critical transition from pro-inflammatory eicosanoids (PGE2, LTB4) to pro-resolving mediators. This switch failure underlies chronic inflammatory conditions across all systems.
Key Clinical Applications:
Chronic Pain Syndromes: MaR1 deficiency or impaired production correlates with persistent pain states. Unlike opioids (which suppress pain perception via mu-opioid receptors but impair resolution), MaR1 simultaneously reduces nociception AND promotes tissue repair. Clinical threshold: plasma MaR1 <20 pg/mL associated with chronic pain persistence. Intervention: Omega-3 supplementation (2-4g EPA+DHA daily, emphasizing DHA >1.5g) to restore substrate availability.
Resolution Failure in IBD/Arthritis: Patients with Crohn's disease, ulcerative colitis, and rheumatoid arthritis demonstrate 60-80% lower MaR1 levels compared to healthy controls. The 12-LOX enzyme expression is often reduced in chronic inflammatory states (negative feedback loop). This connects to the 5 plus 2 plus 1 metamodelβsystemic inflammation persists because the resolution system is starved of substrate and enzymatic capacity.
Metabolic Inflammation: In Type 2 Diabetes and obesity, adipose tissue macrophages fail to produce adequate MaR1 despite elevated inflammatory signals. This perpetuates metaflammation and insulin resistance. MaR1 administration in animal models restores insulin sensitivity by resolving adipose tissue inflammation and reducing TNF-Ξ± and IL-6 production from adipocytes.
Neuroprotection: Following stroke, traumatic brain injury, or in Alzheimer's Disease, MaR1 promotes neuroregeneration and reduces microglia activation. It crosses the blood-brain barrier and activates resolution programs in CNS tissue. This links to neuroinflammation as a core driver of neurodegenerative disease.
Post-Surgical Recovery: MaR1 levels predict surgical recovery speed. Low pre-operative MaR1 (<30 pg/mL) associates with prolonged healing times, increased infection risk, and chronic post-surgical pain. Pre-operative DHA loading (2-3 weeks, 2g/day) can double tissue MaR1 capacity.
Evolutionary Mismatch Context: Modern Western diets (omega-6:omega-3 ratio of 15-20:1 vs ancestral 1-4:1) create systemic DHA deficiency, impairing the entire SPM biosynthetic machinery. This represents a fundamental mismatch between our evolutionary programming (which assumes abundant marine/terrestrial omega-3 sources) and modern reality (grain-fed animals, seed oil dominance).
Intervention Hierarchy:
- Restore substrate: high-dose omega-3 supplementation, emphasizing DHA
- Support enzymatic function: ensure adequate cofactors (vitamin B6, magnesium) for lipoxygenase activity
- Reduce competing pathways: minimize omega-6 overload (corn, soybean, sunflower oils)
- Address systemic acidosis: chronic latent acidosis impairs SPM synthesis (optimize alkaline reserve)
- Consider direct SPM supplementation: emerging therapeutic approach with synthetic MaR1 analogs
- MaR1 was first identified and characterized in 2009 by Serhan's laboratory from resolving exudates
- Name derives from "macrophage mediator in resolving inflammation"
- Molecular weight: 360.5 Da; chirality crucial for bioactivity (7R,14S stereochemistry)
- Produced primarily by M2-polarized macrophages expressing high 12-LOX
- Acts through LGR6 (leucine-rich repeat-containing G protein-coupled receptor 6) with Kd ~50 nM
- Enhances efferocytosis by 200-400% in vitro at 10 nM concentration
- Reduces neutrophil infiltration by 40-60% when administered at inflammation onset
- In sepsis models, MaR1 administration improves survival from 40% to 80% (mouse peritonitis)
- Promotes peripheral nerve regeneration and functional recovery in sciatic nerve injury models
- Human plasma concentrations: healthy adults 10-50 pg/mL; chronic pain patients <15 pg/mL
- Tissue concentrations peak at 12-24 hours post-inflammatory stimulus during resolution phase
- Requires adequate DHA membrane incorporation (>4% of membrane phospholipids)
- Half-life in circulation: 4-6 hours; tissue retention longer (8-12 hours)
- Cross-talks with Resolvins and Protectins in resolution networks (synergistic effects)
- Metabolically inactivated by 15-PGDH enzyme to 7R-keto-MaR1 (inactive metabolite)
- Maresins β MaR1 is the prototypic founding member; MaR2 is the second identified maresin with distinct receptor (RORΞ± > LGR6)
- Specialized pro-resolving mediators (SPMs) β MaR1 is one of four major SPM families alongside resolvins, protectins, and lipoxins
- DHA β essential and rate-limiting precursor for all maresin biosynthesis; tissue DHA depletion eliminates MaR1 production
- 12-LOX β key biosynthetic enzyme; expression levels determine macrophage MaR1-producing capacity
- M2 macrophages β primary cellular source of MaR1; M2 polarization increases 12-LOX expression 5-10 fold
- Efferocytosis β MaR1's signature function; enhances apoptotic cell clearance without triggering secondary inflammation
- Lipid mediator class switching β MaR1 production exemplifies the metabolic shift from eicosanoid storm to SPM resolution
- Omega-3 β dietary intervention target; omega-3 supplementation directly increases MaR1 biosynthetic capacity
- Resolution β MaR1 defines active resolution; its presence marks transition from inflammation to repair
- Inflammation β MaR1 is produced in response to inflammatory signals but acts to resolve rather than propagate them
- Neutrophils β MaR1 reduces neutrophil tissue infiltration and accelerates their clearance from inflamed sites
- LGR6 β primary MaR1 receptor mediating resolution and analgesic effects; couples to GΞ±i signaling
- RORΞ± β secondary nuclear receptor for MaR1; regulates gene transcription of resolution program
- Neuropathic pain β MaR1 reduces pain through TRPV1 modulation and spinal cord neuroinflammation resolution
- Chronic pain β MaR1 deficiency perpetuates pain; supplementation shows analgesic effects in clinical studies
- RvD1 β synergistic SPM; co-administration with MaR1 produces additive resolution effects
- Protectins β parallel DHA-derived SPM family; protectin D1 shares resolution mechanisms with MaR1
- COX-2 β enzyme inhibited by NSAIDs; COX-2 inhibition can impair SPM biosynthesis including maresins
- 15-LOX β related lipoxygenase producing resolvins; enzymatic network for SPM diversity
- PLA2G7 β phospholipase releasing DHA from membrane stores; initiates SPM biosynthetic cascade
- Resolvins β sister SPM family from EPA and DHA; coordinate with maresins in resolution programs
- Type 2 Diabetes β maresin deficiency in adipose tissue perpetuates metabolic inflammation and insulin resistance
- Rheumatoid arthritis β MaR1 levels inversely correlate with disease activity; deficiency promotes joint destruction
- IBD β inflammatory bowel disease patients show profoundly reduced MaR1 in intestinal mucosa
- Alzheimer's Disease β brain MaR1 levels decline with disease progression; neuroinflammation resolution failure
- Obesity β adipose tissue produces insufficient MaR1 despite chronic inflammation; resolution deficit
- Metaflammation β MaR1 administration resolves metabolic inflammation in visceral fat
- TRPV1 β pain receptor modulated by MaR1; mechanism of analgesic action
- Fibroblasts β MaR1 stimulates collagen synthesis and extracellular matrix remodeling during tissue repair
- Collagen β MaR1 promotes organized collagen deposition rather than fibrotic scarring
- TGF-beta β cytokine upregulated by MaR1-activated macrophages; drives tissue repair programs
- NF-ΞΊB β transcription factor inhibited by MaR1 signaling; reduces pro-inflammatory gene expression